Samsung Bioepis’ Stelara Biosimilar Shows Long-Term Similarity In Plaque Psoriasis
Also, FDA Reviews Hadlima Biosimilar To Humira Based On New Interchangeability Data
Hot off the press, Samsung Bioepis reports final data for its ustekinumab biosimilar SB17 in plaque psoriasis ahead of potential US market entry early next year, and gives more data on adalimumab biosimilar Hadlima to support interchangeability.
